A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy | NCT04281511 | Trialant
CompletedObservationalUpdated Nov 13, 2023
A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy
A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy
ClinicalTrials.gov ID
NCT04281511
Lead Sponsor
National Cancer Center, KoreaOTHER_GOV
Overall Status
Completed
Study Type
Observational
Enrollment
238Actual
Last Update Posted
Nov 13, 2023Actual
Start Date
Apr 3, 2019Actual
Primary Completion Date
Sep 30, 2023Actual
Completion Date
Sep 30, 2023Actual
Official Title
A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy
Brief Summary
Based on the literature, the pancreatic cancer treatment predictor biomarker, which is used in the domestic clinical field, is actually applied to the pancreatic cancer patient cohort of the National Cancer Center.
To systematically prospectively identify prospective treatment response biomarkers for Pancreatic Cancer Cohort in the National Cancer Center
Detailed Description
Immunohistochemistry and gene test for hENT1, DCK, SMAD4, CES2, BRCA 1/2,PALB2, MMRd, MSI, Tumor Ag and etc. on Cancer sample
Collect data of Biomarker for pancreatic cancer
Compare with Big data and Cohort study in National cancer center
The number of subjects is changed by statistical consideration. 218->238
Pancreatic Cancer
No interventions
There are no interventions for this study.
Ages Eligible for Study
Child (0-17)Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Pathologically Confirmed Pancreatic Cancer Patients
Exclusion Criteria:
Subjects who do not agree with the study
Observational Model
Cohort
Time Perspective
Prospective
No central contacts
There are no central contacts for this study.
NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong-gu,